<?xml version='1.0' encoding='utf-8'?>
<document id="28435142"><sentence text="Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access." /><sentence text="Clinical drug-drug interactions (DDIs) can occur when multiple drugs are taken by the same patient" /><sentence text=" Significant DDIs can result in clinical toxicity or treatment failure" /><sentence text=" Therefore, DDI assessment is an integral part of drug development and the benefit-risk assessment of new therapies" /><sentence text=" Regulatory agencies including the Food and Drug Administration, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency of Japan have made recommendations in their DDI guidance documents on various methodologies (inÂ vitro, in silico, and clinical) to assess DDI potential and inform patient management strategies"><entity charOffset="253-259" id="DDI-PubMed.28435142.s5.e0" text="silico" /></sentence><sentence text=" This commentary focuses on clinical DDI evaluation for the purpose of drug development and regulatory evaluation" /><sentence text="" /></document>